(MENAFN- GetNews)
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ankylosing Spondylitis pipeline constitutes 20+ key companies continuously working towards developing 20+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details
“Ankylosing Spondylitis Pipeline Insight, 2024 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ankylosing Spondylitis Market..
Some of the key takeaways from the Ankylosing Spondylitis Pipeline Report:
Companies across the globe are diligently working toward developing novel Ankylosing Spondylitis treatment therapies with a considerable amount of success over the years.
Ankylosing Spondylitis companies working in the treatment market are Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others , are developing therapies for the Ankylosing Spondylitis treatment
Emerging Ankylosing Spondylitis therapies in the different phases of clinical trials are- KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others are expected to have a significant impact on the Ankylosing Spondylitis market in the coming years.
In October 2023, RINVOQ by AbbVie is prescribed for adults with active ankylosing spondylitis who have not responded satisfactorily to conventional therapy.
In October 2023, In the European Union, bimekizumab has received approval for addressing moderate to severe plaque psoriasis in adults eligible for systemic therapy. It is also approved for treating active psoriatic arthritis and active axSpA in adults, encompassing both non-radiographic axSpA and ankylosing spondylitis, also recognized as radiographic axSpA. Note that labeling information may vary in other approved regions, and it is advisable to refer to local prescribing guidelines. It is crucial to highlight that the efficacy and safety of bimekizumab in HS (Hidradenitis Suppurativa) have not been validated, and regulatory authorities worldwide have not granted approval for its use in this indication.
Ankylosing Spondylitis Overview
Ankylosing Spondylitis (AS) is a type of chronic inflammatory arthritis primarily affecting the spine and the sacroiliac joints, which connect the spine to the pelvis.
Get a Free Sample PDF Report to know more about Ankylosing Spondylitis Pipeline Therapeutic Assessment-
Emerging Ankylosing Spondylitis Drugs Under Different Phases of Clinical Development Include:
KIN-1901: Kinevant Sciences
Sonelokimab: MoonLake Immunotherapeutics
QX 002N: Qyuns Therapeutics
SHR-1314: Suzhou Zelgen Biopharmaceuticals
SHR0302: Jiangsu HengRui MedicIne
Jaktinib: Suzhou Zelgen Biopharmaceuticals
Apremilast: Amgen
Ankylosing Spondylitis Route of Administration
Ankylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Intramuscular
Topical.
Ankylosing Spondylitis Molecule Type
Ankylosing Spondylitis Products have been categorized under various Molecule types, such as
Ankylosing Spondylitis Pipeline Therapeutics Assessment
Ankylosing Spondylitis Assessment by Product Type
Ankylosing Spondylitis By Stage and Product Type
Ankylosing Spondylitis Assessment by Route of Administration
Ankylosing Spondylitis By Stage and Route of Administration
Ankylosing Spondylitis Assessment by Molecule Type
Ankylosing Spondylitis by Stage and Molecule Type
DelveInsight's Ankylosing Spondylitis Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Ankylosing Spondylitis product details are provided in the report. Download the Ankylosing Spondylitis pipeline report to learn more about the emerging Ankylosing Spondylitis therapies
Some of the key companies in the Ankylosing Spondylitis Therapeutics Market include:
Key companies developing therapies for Ankylosing Spondylitis are - Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cadilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others.
Ankylosing Spondylitis Pipeline Analysis:
The Ankylosing Spondylitis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Ankylosing Spondylitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ankylosing Spondylitis Treatment.
Ankylosing Spondylitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ankylosing Spondylitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ankylosing Spondylitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Ankylosing Spondylitis drugs and therapies
Ankylosing Spondylitis Pipeline Market Drivers
Rising prevalence of ankylosing spondylitis, increase in Drug Development for Ankylosing spondylitis are some of the important factors that are fueling the Ankylosing Spondylitis Market.
Ankylosing Spondylitis Pipeline Market Barriers
However, lack of early diagnosis of the disease, minimum participation of patients in physical activity . High treatment cost and lack of caregiver and other factors are creating obstacles in the Ankylosing Spondylitis Market growth.
Scope of Ankylosing Spondylitis Pipeline Drug Insight
Coverage: Global
Key Ankylosing Spondylitis Companies: Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others
Key Ankylosing Spondylitis Therapies: KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others
Ankylosing Spondylitis Therapeutic Assessment: Ankylosing Spondylitis current marketed and Ankylosing Spondylitis emerging therapies
Ankylosing Spondylitis Market Dynamics: Ankylosing Spondylitis market drivers and Ankylosing Spondylitis market barriers
Request for Sample PDF Report for Ankylosing Spondylitis Pipeline Assessment and clinical trials
Table of Contents
1. Ankylosing Spondylitis Report Introduction
2. Ankylosing Spondylitis Executive Summary
3. Ankylosing Spondylitis Overview
4. Ankylosing Spondylitis- Analytical Perspective In-depth Commercial Assessment
5. Ankylosing Spondylitis Pipeline Therapeutics
6. Ankylosing Spondylitis Late Stage Products (Phase II/III)
7. Ankylosing Spondylitis Mid Stage Products (Phase II)
8. Ankylosing Spondylitis Early Stage Products (Phase I)
9. Ankylosing Spondylitis Preclinical Stage Products
10. Ankylosing Spondylitis Therapeutics Assessment
11. Ankylosing Spondylitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ankylosing Spondylitis Key Companies
14. Ankylosing Spondylitis Key Products
15. Ankylosing Spondylitis Unmet Needs
16 . Ankylosing Spondylitis Market Drivers and Barriers
17. Ankylosing Spondylitis Future Perspectives and Conclusion
18. Ankylosing Spondylitis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
MENAFN17102024003238003268ID1108791205